Universal reference book for medicines
Product name: BEGRIVAC (BEGRIVAC)

Active substance: inactivated influenza vaccine (surface antigen)

Type: Vaccine for the prevention of influenza

Manufacturer: NOVARTIS VACCINES AND DIAGNOSTICS (Germany)
A typical clinical and pharmacological article
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

PHARMACHOLOGIC EFFECT
Forms high specific immunity against influenza.
Protective titers of antibodies to influenza viruses after vaccination of persons of different ages are determined in 75-92% of vaccinated.
INDICATIONS
Prevention of influenza in adults and children older than 6 months (including with respiratory and cardiovascular diseases, chronic renal failure, diabetes, immunodeficiency, including HIV infection, malignant blood diseases, concomitant therapy with immunosuppressants, cytostatics, radiation therapy, high doses of GKC, in elderly patients (over 65 years), in pregnant women at high risk of influenza.

DOSING MODE
In / m, deltoid muscle or deep sci in the upper third of the outer surface of the shoulder, young children - in the anterolateral lateral surface of the thigh.


Children 6 months-3 years: 0.25 ml once;
in the case of children who had not previously had the flu and unvaccinated - twice with an interval of 4 weeks.

Children over 3 years and adults: 0.5 ml once.


Patients with immunodeficiency can enter the vaccine twice in 0.25 ml with an interval of 4 weeks.

SIDE EFFECT
Often: headache, hyperthermia, malaise, fatigue, tremor, sweating, tenderness in muscles and joints, neuralgia (transiently, disappear after 1-2 days);
rarely - thrombocytopenia, paresthesia, convulsions, encephalomyelitis, neuritis, Guillain-Barre syndrome (there is no clear connection with vaccination); very rarely - vasculitis with transient renal dysfunction, allergic reactions up to shock.

Local reactions: hyperemia, compaction, swelling and tenderness at the injection site, ecchymosis.

CONTRAINDICATIONS
hypersensitivity, incl.
to chicken protein and aminoglycosides;
- allergic reactions to the previous administration of the vaccine;

- acute feverish conditions or exacerbation of a chronic disease (vaccination is carried out after recovery or remission);

- non-severe ARVI (vaccination is performed after normalization of body temperature).

PREGNANCY AND LACTATION
Preclinical studies have shown that the vaccine does not have embryotoxic and teratogenic effects.
The decision on vaccination of pregnant women should be taken by a doctor individually, taking into account the risk of infection with influenza and possible complications of influenza infection. Vaccination is most safe in the II-III trimesters of pregnancy.
Does not have teratogenic and toxic effects on the fetus.
Possible vaccination during lactation.
SPECIAL INSTRUCTIONS
Vaccination is carried out annually in the autumn-winter period.
It is possible to vaccinate at the beginning of an epidemic rise in the incidence of influenza.
Not allowed in / in the introduction.


Against the background of severe ARVI, acute intestinal diseases, etc., vaccination is carried out after the normalization of body temperature.

On the day of vaccination, the vaccinated should be examined by a physician (paramedic) with obligatory thermometry.
At a body temperature above 37 ° C, vaccination is not performed.
The vaccination rooms should have medicines for anti-shock therapy (epinephrine, GCS, etc.).


After vaccination, it is possible to obtain false positive results of serological tests for enzyme-linked immunosorbent assays, which are caused by the production of IgM.


The drug may contain trace amounts of gentamicin.


Does not affect the ability to concentrate and the speed of the psychomotor reaction.


The vaccinated should be monitored by a health worker within 30 minutes after immunization.


The vials are opened and the vaccination procedure is carried out with strict adherence to aseptic and antiseptic rules: before opening the ampoule, the ampulla neck is wiped with cotton wool soaked with 70% ethanol, the ampoule is opened, the vaccine is taken into a disposable syringe and excess air is removed from the syringe.Ethanol wipe the skin at the injection site.


The drug in the opened ampoule is not subject to storage.


The preparation is not suitable for use in ampoules with broken integrity or marking, with a change in physical properties (color, transparency), with expired shelf life, if the requirements for storage conditions are violated.

DRUG INTERACTION
The vaccine can be used concomitantly with other inactivated vaccines (contraindications to each of the vaccines used must be taken into account, drugs must be injected into different parts of the body, with different syringes).

SCS and immunosuppressants reduce the immune response to the administration of the vacc
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!